Feasibility of Addressing Sexual Dysfunction in Women with Breast and Gynecologic Cancers with a Novel Mobile Application
Launched by THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER, HOUSTON · Nov 16, 2024
Trial Information
Current as of July 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how a new mobile app can help women with breast and gynecologic cancers who are experiencing sexual dysfunction, which means they might have difficulties related to sexual activity. The study will identify these issues using a survey called the Female Sexual Function Index (FSFI) and will allow participants to talk with healthcare providers about their needs over a six-month period. The goal is to see if medical help can improve their situation.
To join the study, participants must be women aged 65 to 74 who have been diagnosed with breast cancer or any type of gynecologic cancer, such as uterine or cervical cancer. They will need to complete a survey and use the mobile app called ROSY, which is currently only available in English. It's important to note that pregnant women cannot participate in this study. Since the trial is not yet recruiting, interested individuals will need to wait for more updates on when they can enroll.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Patient with a current or historic diagnosis of breast cancer or gynecologic cancer (uterine ovarian, fallopian tube, peritoneal, cervical, vulva, or vaginal cancers)
- • Agree to participate in the study with completion of survey and use of ROSY mobile application
- Exclusion Criteria:
- • Currently pregnant
- • Non-English speaking (ROSY is currently is only available is in English).
About The University Of Texas Health Science Center, Houston
The University of Texas Health Science Center at Houston (UTHealth) is a leading academic institution dedicated to advancing health through education, research, and clinical practice. As a prominent sponsor of clinical trials, UTHealth leverages its extensive resources and expertise in biomedical research to facilitate innovative studies aimed at improving patient outcomes. The institution is committed to fostering a collaborative environment that promotes scientific discovery and the translation of research findings into effective healthcare solutions, all while adhering to the highest ethical standards and regulatory guidelines. With a multidisciplinary approach, UTHealth plays a critical role in addressing complex health challenges and enhancing the quality of life in diverse communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Trial Officials
Lavanya P Parsons, MD
Principal Investigator
The University of Texas Health Science Center, Houston
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported